<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        68-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SCOLTA 10MG F.C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        31.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma Saudi " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Pharmacotherapeutic group: </strong></p><p>SCOLTA&reg;&nbsp;(Rosuvastatin) belongs to a group of medicines called statins.</p><p><strong>&nbsp;You have been prescribed </strong>SCOLTA&reg;&nbsp;<strong>because:</strong></p><p>You have a high cholesterol level. This means you are at risk from a heart attack or stroke. SCOLTA&reg;&nbsp;is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p>You have been advised to take a statin, because changing your diet and doing more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking SCOLTA&reg;.</p><p>Or</p><p>You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to buildup of fatty deposits in your arteries.</p><p><strong>Therapeutic indications:</strong></p><p>SCOLTA&reg;&nbsp;is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol. There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><p>&bull;SCOLTA&reg;&nbsp;can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</p><p>&bull;It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</p><p>&nbsp;</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.&nbsp; Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p>You need to<strong> keep taking</strong> SCOLTA&reg;, even if it has got your cholesterol to the right level, because <strong>it prevents your cholesterol levels from creeping up again</strong> and causing buildup of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take </strong>SCOLTA&reg;<strong>: </strong></p><p>&bull;If you have ever had an allergic reaction to SCOLTA&reg;, or to any of its ingredients.</p><p>&bull;If you are pregnant or breast-feeding. If you become pregnant while taking SCOLTA&reg;&nbsp;stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking SCOLTA&reg;&nbsp;by using suitable contraception.</p><p>&bull;If you have liver disease.</p><p>&bull;If you have severe kidney problems.</p><p>&bull;If you have repeated or unexplained muscle aches or pains.</p><p>&bull;If you take a drug called ciclosporin (used, for example, after organ transplants).</p><p><strong>In addition, do not take </strong>SCOLTA&reg;&nbsp;<strong>40 mg (the highest dose): </strong></p><p>&bull;If you have moderate kidney problems (if in doubt, please ask your doctor).</p><p>&bull;If your thyroid gland is not working properly.</p><p>&bull;If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</p><p>&bull;If you regularly drink large amounts of alcohol.</p><p>&bull;If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull;If you take other medicines called fibrates to lower your cholesterol.</p><p>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p><strong>b. Take special care with </strong></p><p>Talk to your doctor or pharmacist before taking SCOLTA&reg;.</p><p>&bull;If you have problems with your kidneys.</p><p>&bull;If you have problems with your liver.</p><p>&bull;If you have had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p>&bull;If you regularly drink large amounts of alcohol.</p><p>&bull;If your thyroid gland is not working properly.</p><p>&bull;If you take other medicines called fibrates to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.</p><p>&bull;If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir and/or atazanavir.</p><p>&bull;If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection), orally or by injection. The combination of fusidic acid and SCOLTA&reg;&nbsp;can lead to serious muscle problems (rhabdomyolysis).</p><p>&bull;If you are over 70 (as your doctor needs to choose the right start dose of SCOLTA&reg;&nbsp;to suit you)</p><p>&bull;If you have severe respiratory failure.</p><p>&bull;If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of SCOLTA&reg;&nbsp;to suit you.</p><p>&nbsp;</p><p>If any of the above applies to you (or if you are not sure):</p><p>&bull;Do not take SCOLTA&reg;&nbsp;40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of SCOLTA&reg;.</p><p>&bull;In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with SCOLTA&reg;.</p><p>&bull;While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>Children and adolescents</p><p>&bull;If the patient is under 6 years old: SCOLTA&reg;&nbsp;should not be given to children younger than 6 years.</p><p>&bull;If the patient is below 18 years of age: The SCOLTA&reg;&nbsp;40 mg tablet is not suitable for use in children and adolescents below 18 years of age.</p><p>&nbsp;</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines</p><p>Tell your doctor if you are taking any of the following: ciclosporin (used for example, after organ transplants), warfarin or clopidogrel (or any other drug used for thinning the blood), fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe), indigestion remedies (used to neutralise acid in your stomach), erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see below and Warnings and precautions), an oral contraceptive (the pill), hormone replacement therapy or anti-viral medications such as ritonavir with lopinavir and/or atazanavir or simeprevir (used to treat infections, including HIV or hepatitis C infection &ndash; please see Warnings and precautions). The effects of these medicines could be changed by SCOLTA&reg;&nbsp;or they could change the effect of SCOLTA&reg;.</p><p><strong>If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart</strong> SCOLTA&reg;<strong>. Taking</strong> SCOLTA&reg;&nbsp;<strong>with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis.</strong></p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding:</strong></p><p>Do not take SCOLTA&reg;&nbsp;if you are pregnant or breast-feeding. If you become pregnant while taking SCOLTA&reg;&nbsp;stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking SCOLTA&reg;&nbsp;by using suitable contraception. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>Most people can drive a car and operate machinery while using SCOLTA&reg;&nbsp;&ndash; it will not affect their ability. However, some people feel dizzy during treatment with SCOLTA&reg;. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p>&nbsp;</p><p><strong>g. Important information about one of the ingredients in </strong>SCOLTA&reg;</p><p>SCOLTA&reg;&nbsp;contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk sugar), contact your doctor before taking SCOLTA&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Usual doses in adults </strong></p><p>If you are taking SCOLTA&reg;&nbsp;for high cholesterol:</p><p>Your treatment with SCOLTA&reg;&nbsp;must start with the <strong>5 mg or the 10 mg dose</strong>, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&bull;Your cholesterol level.</p><p>&bull;The level of risk you have of experiencing a heart attack or stroke.</p><p>&bull;Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of SCOLTA&reg;&nbsp;will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&bull;You are of <strong>Asian origin</strong> (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull;You are <strong>over 70 years of age.</strong></p><p>&bull;You have moderate kidney problems.</p><p>&bull;You are at risk of muscle aches and pains (myopathy).</p><p>&nbsp;</p><p><strong>Increasing the dose and maximum daily dose</strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of SCOLTA&reg;&nbsp;that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of SCOLTA&reg;&nbsp;is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p><strong>If you are taking</strong> SCOLTA&reg;<strong>&nbsp;to reduce your risk of having a heart attack, stroke or related health problems:</strong></p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p><strong>Use in children and adolescents aged 6-17 years </strong></p><p>The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg per day, and your doctor may gradually increase your dose to find the right amount of SCOLTA&reg;&nbsp;for you. The maximum daily dose of SCOLTA&reg;&nbsp;is 10 or 20 mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. SCOLTA&reg;&nbsp;40 mg tablet should<strong> not </strong>be used by children.</p><p><strong>Taking your tablets </strong></p><p>Swallow each tablet whole with a drink of water.</p><p>Take SCOLTA&reg;&nbsp;once daily, you can take it at any time of the day with or without food.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p>Regular cholesterol checks</p><p>&nbsp;It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of SCOLTA&reg;&nbsp;that is right for you.</p><p>&nbsp;</p><p><strong>a.If you take more</strong> SCOLTA&reg;<strong>&nbsp;than you should</strong></p><p>Contact your doctor or nearest hospital for advice. If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking SCOLTA&reg;.</p><p>&nbsp;</p><p><strong>b.If you forget to take</strong></p><p>&nbsp;Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>c.If you stop taking</strong> SCOLTA&reg;&nbsp;&nbsp;</p><p>Talk to your doctor if you want to stop taking SCOLTA&reg;. Your cholesterol levels might increase again if you stop taking SCOLTA&reg;.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p><strong>Stop taking</strong> SCOLTA&reg;&nbsp;<strong>and seek medical help immediately</strong> if you have any of the following allergic reactions:</p><p>&bull;Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat.</p><p>&bull;Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing.</p><p>&bull;Severe itching of the skin (with raised lumps).</p><p><strong>Also, stop taking</strong> SCOLTA&reg;&nbsp;<strong>and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as rhabdomyolysis.</p><p><strong>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients): </strong></p><p>&bull;Headache</p><p>&bull;Stomach pain</p><p>&bull;Constipation</p><p>&bull;Feeling sick</p><p>&bull;Muscle pain</p><p>&bull;Feeling weak</p><p>&bull;Dizziness</p><p>&bull;An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your SCOLTA&reg;&nbsp;tablets (only SCOLTA&reg;40 mg)</p><p>&bull;Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p><strong>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients):</strong></p><p>Rash, itching or other skin reactions</p><p>An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your SCOLTA&reg;&nbsp;tablets (only SCOLTA&reg;&nbsp;5 mg, 10 mg and 20 mg).</p><p><strong>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients): </strong></p><p>&bull;Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). <strong>If you think you are having an allergic reaction, then stop taking </strong>SCOLTA&reg;&nbsp;and seek medical help immediately</p><p>&bull;Muscle damage in adults &ndash; as a precaution, <strong>stop taking </strong>SCOLTA&reg;&nbsp;<strong>and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than expected</p><p>&bull;A severe stomach pain (inflamed pancreas)</p><p>&bull;Increase in liver enzymes in the blood</p><p>&bull;Bleeding or bruising more easily than normal due to low level of blood platelets.</p><p><strong>Very rare possible side effects (these may affect less than 1 in 10,000 patients):</strong></p><p>&bull;Jaundice (yellowing of the skin and eyes)</p><p>&bull;Hepatitis (an inflamed liver)</p><p>&bull;Traces of blood in your urine</p><p>&bull;Damage to the nerves of your legs and arms (such as numbness)</p><p>&bull;Joint pain</p><p>&bull;Memory loss</p><p>&bull;Breast enlargement in men (gynecomastia)</p><p><strong>Side effects of unknown frequency may include:</strong></p><p>&bull;Diarrhea (loose stools)</p><p>&bull;Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals)</p><p>&bull;Cough</p><p>&bull;Shortness of breath</p><p>&bull;Edema (swelling)</p><p>&bull;Sleep disturbances, including insomnia and nightmares</p><p>&bull;Sexual difficulties</p><p>&bull;Depression</p><p>&bull;Breathing problems, including persistent cough and/or shortness of breath or fever</p><p>&bull;Tendon injury</p><p>&bull;Muscle weakness that is constant</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;Keep out of the reach and sight of children.</p><p>&bull; Do not store above 30&deg;C.</p><p>&bull;Do not use SCOLTA&reg;&nbsp;after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.</p><p>&bull;Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is:</strong> Rosuvastatin</p><p>&bull;SCOLTA&reg;&nbsp;<strong>10:</strong> Each film coated tablet contains Rosuvastatin Calcium equivalent to Atorvastatin 10 mg.</p><p>&bull;SCOLTA&reg;&nbsp;<strong>20:</strong> Each film coated tablet contains Rosuvastatin Calcium equivalent to Atorvastatin 20 mg.</p><p>&bull;SCOLTA&reg;&nbsp;<strong>40:</strong> Each film coated tablet contains Rosuvastatin Calcium equivalent to Atorvastatin 40 mg.</p><p><strong>Other ingredients are: </strong></p><p>SCOLTA&reg;&nbsp;<strong>Excipients:</strong> Calcium Phosphate anhydrous, Crosspovidone, Microcrystalline Cellulose, Lactose, Magnesium Stearate, Opadry White OY-L, Red Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film coated tablets.
Physical Description: 
•SCOLTA® 10mg F/C Tablets: Pink round biconvex tablet embossed with E57 on one side, and plain on the other side.
•SCOLTA® 20mg F/C Tablets: Pink round biconvex tablet embossed with E55 on one side, and plain on the other side.
•SCOLTA® 40mg F/C Tablets: Oval pink non-scored film coated tablets, embossed with E54 on one side and plain on the other side.
Tablets packed in Aluminum /Aluminum blisters, in carton box with a folded leaflet, in pack size of 30 F/C Tablets; (10 Tablets /blister, 3 blisters/ pack).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by:</strong></p><p>United Pharmaceutical Mfg. Co. Ltd.&nbsp; - Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in Oct,2020; version number: SPM190353
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>المجموعة العلاجية: </strong></p><p dir="RTL">ينتمي <strong>&nbsp;سكولتا</strong>&nbsp; (روسوفاستاتن) إلى مجموعة من الأدوية تسمى الستاتين.</p><p dir="RTL"><strong>لقد تم وصف&nbsp; سكولتا&nbsp; لك بسبب:</strong></p><p dir="RTL">لديك مستوى عال من الكولسترول. وهذا يعني أنك في خطر لحدوث نوبة قلبية أو سكتة دماغية. يستخدم <strong>&nbsp;سكولتا</strong> في البالغين والمراهقين والأطفال من عمر 6 سنوات أو أكثر لعلاج ارتفاع الكولسترول في الدم.</p><p dir="RTL">قد نصحت باتخاذ ستاتين، لأن تغيير النظام الغذائي الخاص بك وممارسة الرياضة لم تكن كافية لتصحيح مستويات الكولسترول. يجب أن تستمر مع اتباع نظام غذائي منخفض الكولسترول وممارسة التمارين الرياضية عند تناولك <strong>&nbsp;سكولتا</strong> . أو</p><p dir="RTL">لديك عوامل أخرى تزيد من خطر الإصابة بأزمة قلبية أو سكتة دماغية أو مشاكل صحية ذات صلة.</p><p dir="RTL">النوبة القلبية والسكتة الدماغية وغيرها من المشاكل يمكن أن يكون سببه مرض يسمى تصلب الشرايين. ويرجع تصلب الشرايين إلى تراكم الرواسب الدهنية في الشرايين.</p><p dir="RTL"><strong>الاستعمالات العلاجية:</strong></p><p dir="RTL">يستعمل <strong>&nbsp;سكولتا</strong>&nbsp; لتصحيح مستويات المواد الدهنية في الدم والتي تسمى الدهون، وأكثرها شيوعا هي الكولسترول. هناك أنواع مختلفة من الكولسترول وجدت في الدم - الكولسترول &laquo;السيء&raquo; (الكولسترول منخفض الكثافة) و الكولسترول &laquo;الجيد&raquo; (الكولسترول مرتفع الكثافة).</p><p dir="RTL">&bull; يمكن <strong>لـ</strong> <strong>&nbsp;سكولتا</strong>&nbsp; تقليل الكولسترول &laquo;السيء&raquo; وزيادة الكولسترول &laquo;الجيد&raquo;.</p><p dir="RTL">&bull; يعمل من خلال المساعدة على منع إنتاج جسمك من الكولسترول &laquo;السيء&raquo;. كما أنه يحسن قدرة الجسم على إزالته من الدم.</p><p dir="RTL">بالنسبة لمعظم الناس، فإن ارتفاع الكولسترول لا يؤثر على الطريقة التي يشعرون بها، لأنها لا تنتج أي أعراض. ومع ذلك، إذا تركت دون علاج، يمكن أن تتراكم الرواسب الدهنية على جدران الأوعية الدموية مما تسبب في تضييقها. في بعض الأحيان، فإن هذه الأوعية الدموية المتضيقة يمكن أن تغلق والتي يمكن أن تقطع إمدادات الدم إلى القلب أو الدماغ مما يؤدي إلى حدوث نوبة قلبية أو سكتة دماغية. عن طريق خفض مستويات الكولسترول الخاص بك، يمكنك تقليل خطر الإصابة بأزمة قلبية، وسكتة دماغية أو المشاكل الصحية ذات الصلة.</p><p dir="RTL">تحتاج إلى الاستمرار في تناول <strong>&nbsp;سكولتا</strong> ، حتى لو عاد الكولسترول إلى المستوى الصحيح، لأنه يمنع مستويات الكولسترول الخاص بك من الارتفاع مرة أخرى وتسبب تراكم الرواسب الدهنية. ومع ذلك، يجب أن تتوقف إذا أخبرك طبيبك أن تفعل ذلك، أو كنت قد أصبحت حاملا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ. لا تأخذ سكولتا&nbsp; :</strong></p><p dir="RTL">&bull; إذا كان لديك في أي وقت سابق رد فعل تحسسي لـ <strong>سكولتا</strong> ، أو لأي من مكوناته.</p><p dir="RTL">&bull; إذا كنت حاملا أو مرضعة. إذا أصبحت حاملا أثناء تناول <strong>سكولتا</strong>&nbsp; يجب عليك التوقف عن تناوله فورا وأخبري طبيبك. يجب على النساء تجنب الحمل أثناء تناول <strong>سكولتا</strong>&nbsp; وذلك باستخدام وسائل منع حمل مناسبة.</p><p dir="RTL">&bull; إذا كان لديك مرض في الكبد.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل حادة في الكلى.</p><p dir="RTL">&bull; إذا كان لديك أي آلام أو آلام متكررة أو غير مبررة في العضلات.</p><p dir="RTL">&bull; إذا تناولت دواء يدعى سيكلوسبورين (مستخدم، على سبيل المثال، بعد زراعة الأعضاء ).</p><p dir="RTL"><strong>وبالإضافة إلى ذلك، لا تأخذ سكولتا&nbsp; 40 ملغم (أعلى جرعة):</strong></p><p dir="RTL">&bull; إذا كان لديك مشاكل معتدلة في الكلى (إذا كنت في شك، يرجى استشارة الطبيب).</p><p dir="RTL">&bull; إذا كانت الغدة الدرقية لا تعمل بشكل صحيح.</p><p dir="RTL">&bull; إذا كان لديك أي آلام أو آلام متكررة أو غير مبررة في العضلات، وتاريخ شخصي أو عائلي لمشاكل العضلات، أو تاريخ مسبق لمشاكل العضلات عند تناول أدوية أخرى مخفضة للكولسترول.</p><p dir="RTL">&bull; إذا كنت تشرب كميات كبيرة من الكحول بانتظام.</p><p dir="RTL">&bull; إذا كنت من أصل آسيوي (اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية).</p><p dir="RTL">&bull; إذا تناولت أدوية أخرى تسمى فيبرات لخفض الكولسترول.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو كنت في شك)، يرجى العودة ورؤية الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال سكولتا</strong>&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول <strong>سكولتا</strong> .</p><p dir="RTL">&bull; إذا كان لديك مشاكل مع الكلية.</p><p dir="RTL">&bull; إذا كان لديك مشاكل في الكبد.</p><p dir="RTL">&bull; إذا كان لديك آلام أو آلام متكررة أو غير مبررة في العضلات، أو تاريخ شخصي أو عائلي لمشاكل العضلات، أو تاريخ سابق لمشاكل العضلات عند تناول أدوية أخرى لخفض الكولسترول. أخبر طبيبك على الفور إذا كان لديك آلام في العضلات غير مبررة أو آلام خاصة إذا كنت تشعر بالتوعك أو لديك حمى. أخبر طبيبك أو الصيدلي إذا كان لديك ضعف عضلي ثابت.</p><p dir="RTL">&bull; إذا كنت تشرب كميات كبيرة من الكحول بانتظام.</p><p dir="RTL">&bull; إذا كانت الغدة الدرقية لا تعمل بشكل صحيح.</p><p dir="RTL">&bull; إذا تناولت أدوية أخرى تسمى فيبرات لخفض الكولسترول. يرجى قراءة هذه النشرة بعناية، حتى لو كنت قد اتخذت أدوية أخرى لارتفاع الكولسترول من قبل.</p><p dir="RTL">&bull; إذا تناولت أدوية تستخدم لعلاج عدوى فيروس العوز المناعي البشري. ريتونافير مع لوبينافير و/ أو أتازانافير.</p><p dir="RTL">&bull; إذا كنت تتناول أو تناولت في آخر 7 أيام دواء يدعى حمض الفوسيديك (دواء لعلاج العدوى البكتيرية )، عن طريق الفم أو عن طريق الحقن. مزيج من حمض الفوسيديك و <strong>سكولتا</strong>&nbsp; يمكن أن يؤدي إلى مشاكل خطيرة في العضلات (انحلال العضلات المخططة).</p><p dir="RTL">&bull; إذا کنت أکبر من 70 سنة (کما یحتاج طبیبك إلی اختیار جرعة بداية مناسبة من <strong>سكولتا</strong>&nbsp; لتناسبك)</p><p dir="RTL">&bull; إذا كان لديك فشل شديد في الجهاز التنفسي.</p><p dir="RTL">&bull; إذا كنت من أصل آسيوي - أي اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية. يحتاج طبيبك إلى اختيار جرعة بداية مناسبة من <strong>سكولتا</strong>&nbsp; لتناسبك.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدا):</p><p dir="RTL">&bull; لا تتناول <strong>سكولتا</strong> 40 ملغم (أعلی جرعة) وتحقق مع طبیبك أو الصیدلي قبل أن البدء فعلیا في تناول أي جرعة من <strong>سكولتا</strong> .</p><p dir="RTL">&bull; في عدد قليل من الناس، يمكن أن يؤثر الستاتين على الكبد. يتم التعرف على هذا عن طريق اختبار بسيط الذي يبحث عن زيادة مستويات انزيمات الكبد في الدم. لهذا السبب، سيقوم طبيبك عادة بإجراء هذا فحص الدم (اختبار وظائف الكبد) قبل وأثناء العلاج مع <strong>سكولتا</strong> .</p><p dir="RTL">&bull; أثناء تناولك هذا الدواء، سيراقبك الطبيب عن كثب إذا كنت مصابا بداء السكري أو معرض لخطر الإصابة بمرض السكري. من المحتمل أن تكون عرضة لخطر الإصابة بمرض السكري إذا كان لديك مستويات عالية من السكريات والدهون في الدم، تعاني من زيادة في الوزن، وارتفاع ضغط الدم.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">&bull; إذا كان المريض دون سن 6 سنوات: لا ينبغي إعطاء <strong>سكولتا</strong>&nbsp; للأطفال الذين تقل أعمارهم عن 6 سنوات.</p><p dir="RTL">&bull; إذا كان المريض أقل من 18 سنة من العمر: قرص <strong>سكولتا</strong> 40 ملغم غير مناسب للاستخدام في الاطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تأخذ أي أدوية أخرى</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أي مما يلي: سيكلوسبورين (يستخدم على سبيل المثال، بعد زراعة الأعضاء)، الوارفارين أو كلوبيدوغريل (أو أي دواء آخر يستخدم لتقليل لزوجة الدم)، فيبرات مثل (جيمفيبروزيل، فينوفيبرات) أو أي دواء آخر يستخدم لخفض الكوليستيرول مثل (إيزيتيميب)، وعلاجات عسر الهضم (تستخدم لمعادلة حموضة المعدة)، اريثروميسين (من المضادات الحيوية)، حمض فوسيديك (مضاد حيوي)، وسائل منع الحمل التي تؤخذ عن طريق الفم (حبوب منع الحمل) ، العلاج بالهرمونات البديلة أو الأدوية المضادة للفيروسات مثل ريتونافير مع لوبينافير و / أو أتازانافير أو سيمبريفير (المستخدمة لعلاج الالتهابات، بما في ذلك فيروس عوز المناعة البشرية أو عدوى التهاب الكبد ج). يمكن تغيير آثار هذه الأدوية من قبل <strong>سكولتا</strong>&nbsp; أو أنها يمكن أن تغير تأثير <strong>سكولتا</strong> .</p><p dir="RTL">إذا كنت بحاجة إلى تناول حمض فوسيديك عن طريق الفم لعلاج عدوى بكتيرية سوف تحتاج إلى التوقف مؤقتا عن استخدام هذا الدواء. سيخبرك طبيبك عندما يكون من الآمن إعادة استخدام <strong>سكولتا</strong> . تناول <strong>سكولتا</strong>&nbsp; مع حمض الفوسيديك نادرا ما يؤدي إلى ضعف العضلات، التعب أو الألم (انحلال العضلات المخططة ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. الحمل والرضاعة </strong></p><p dir="RTL">لا تتناولي <strong>سكولتا</strong>&nbsp; إذا كنت حاملا أو مرضعة. إذا أصبحت حاملا أثناء تناول <strong>سكولتا</strong>&nbsp; يجب عليك التوقف عن تناوله فورا وأخبري طبيبك. يجب على النساء تجنب الحمل أثناء تناول <strong>سكولتا</strong>&nbsp; باستخدام وسائل منع الحمل المناسبة. استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. القيادة واستعمال الآلات</strong></p><p dir="RTL">يمكن لمعظم الناس قيادة السيارة وتشغيل الآلات أثناء استخدام <strong>سكولتا</strong>&nbsp; - فإنه لن يؤثر على قدرتهم. ومع ذلك، يشعر بعض الناس بالدوار أثناء العلاج مع <strong>سكولتا</strong> . إذا شعرت بالدوار، استشر طبيبك قبل محاولة القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. معلومات مهمة عن مكون من مكونات سكولتا&nbsp; </strong></p><p dir="RTL">يحتوي <strong>سكولتا</strong> على اللاكتوز. إذا قيل لك من قبل طبيبك أن لديك تعصب لبعض السكريات (مثل اللاكتوز)، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول أقراص <strong>سكولتا</strong>&nbsp; تماما كما أخبرك طبيبك أو الصيدلي. تحقق مع الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><strong>الجرعات الاعتيادية لدى البالغين</strong></p><p dir="RTL">إذا كنت تأخذ <strong>سكولتا</strong>&nbsp; لارتفاع نسبة الكولسترول في الدم:</p><p dir="RTL">يجب أن يبدأ علاجك مع <strong>سكولتا</strong>&nbsp; بجرعة 5 ملغم أو 10 ملغم، حتى لو كنت قد تناولت جرعة أعلى من ستاتين مختلف من قبل. يعتمد اختيار جرعة البداية على:</p><p dir="RTL">&bull; مستوى الكولسترول.</p><p dir="RTL">&bull; مستوى المخاطرة التي تعاني منها إصابتك بأزمة قلبية أو السكتة الدماغية.</p><p dir="RTL">&bull; إذا كان لديك عامل قد يجعلك أكثر حساسية للآثار الجانبية المحتملة.</p><p dir="RTL">يرجى مراجعة الطبيب أو الصيدلي الذي سيحدد جرعة البداية من <strong>سكولتا</strong>&nbsp; التي تناسبك.</p><p dir="RTL">قد يقرر طبيبك أن يعطيك أقل جرعة (5 ملغم) إذا:</p><p dir="RTL">&bull; أنت من أصل آسيوي (اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية).</p><p dir="RTL">&bull; أنت أكبر من 70 سنة من العمر.</p><p dir="RTL">&bull; تعاني من مشاكل معتدلة في الكلى.</p><p dir="RTL">&bull; كنت تعاني من خطر حدوث آلام في العضلات (اعتلال عضلي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زيادة الجرعة والجرعة اليومية القصوى</strong></p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك. هذا لتأخذ كمية <strong>سكولتا</strong>&nbsp; المناسبة لك. إذا كنت قد بدأت بجرعة 5 ملغم، قد يقرر الطبيب مضاعفة هذه الجرعة إلى 10 ملغم، ثم 20 ملغم ثم 40 ملغم إذا لزم الأمر. إذا بدأت بجرعة 10 ملغم، قد يقرر الطبيب مضاعفة هذا إلى 20 ملغم ثم 40 ملغم إذا لزم الأمر. سوف تكون هناك فجوة من أربعة أسابيع بين كل تعديل في الجرعة.</p><p dir="RTL">الجرعة اليومية القصوى من <strong>سكولتا</strong>&nbsp; هي 40 ملغم. هذه الجرعة فقط للمرضى الذين يعانون من ارتفاع مستويات الكولسترول في الدم وارتفاع خطر الإصابة بنوبات قلبية أو سكتة دماغية والتي لم يتم خفض مستويات الكولسترول بما فيه الكفاية باستخدام جرعة 20 ملغم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول سكولتا&nbsp; لتقليل خطر الإصابة بأزمة قلبية أو سكتة دماغية أو مشاكل صحية ذات صلة:</strong></p><p dir="RTL">الجرعة الموصى بها هي 20 ملغم يوميا. ومع ذلك، قد يقرر طبيبك استخدام جرعة أقل إذا كان لديك أي من العوامل المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين الذين تتراوح أعمارهم بين 6-17 سنة</strong></p><p dir="RTL">نطاق الجرعة في الأطفال والمراهقين الذين تتراوح أعمارهم بين 6 إلى 17 سنة هو 5 إلى 20 ملغم مرة واحدة يوميا. جرعة البداية الاعتيادية هي 5 ملغم يوميا، قد يزيد طبيبك جرعتك تدريجيا للوصول للكمية المناسبة لك من <strong>سكولتا</strong> . الجرعة اليومية القصوى من <strong>سكولتا</strong>&nbsp; هي 10 أو 20 ملغم للأطفال الذين تتراوح أعمارهم بين 6 إلى 17 سنة اعتمادا على حالتك الأساسية التي يتم علاجها. تناول الجرعة مرة واحدة في اليوم. يجب عدم استخدام أقراص <strong>سكولتا</strong>&nbsp; 40 ملغم من قبل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ الأقراص</strong></p><p dir="RTL">يجب بلع كل قرص كاملا مع شرب الماء,خذ <strong>سكولتا</strong>&nbsp; مرة واحدة يوميا، يمكنك أن تأخذه في أي وقت من اليوم مع أو بدون الطعام,حاول أن تأخذ الاقراص في نفس الوقت كل يوم لمساعدتك على تذكر ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فحوص الكولسترول الاعتيادية</strong></p><p dir="RTL">&nbsp;من المهم أن تعود إلى طبيبك لفحص مستوى الكولسترول بشكل منتظم، للتأكد من أن نسبة الكولسترول قد وصلت إلى المستوى الصحيح.</p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك بحيث تأخذ كمية <strong>سكولتا</strong>&nbsp; المناسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ</strong><strong>&zwnj;</strong><strong>.إذا تناولت سكولتا&nbsp; أكثر مما يجب</strong></p><p dir="RTL">اتصل بطبيبك أو أقرب مستشفى للحصول على المشورة.</p><p dir="RTL">إذا ذهبت إلى المستشفى أو تلقيت علاجا لحالة أخرى، أخبر الموظفين الطبيين بأنك تتناول <strong>سكولتا</strong> .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. إذا نسيت تناول أقراص سكولتا</strong>&nbsp;</p><p dir="RTL">&nbsp;لا تقلق، فقط خذ الجرعة المجدولة التالية في الوقت الصحيح. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. اذا توقفت عن تناول أقراص سكولتا </strong>&nbsp;</p><p dir="RTL">تحدث مع طبيبك إذا كنت ترغب في التوقف عن تناول <strong>سكولتا</strong> . قد تزيد مستويات الكولسترول مرة أخرى إذا توقفت عن تناول <strong>سكولتا</strong> .إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">وكما هو الحال في جميع الادوية، يمكن أن تسبب أقراص <strong>سكولتا</strong>&nbsp; آثارا جانبية، على الرغم من عدم حدوثها في الجميع.من المهم أن تكون على علم بهذه الآثار الجانبية. وعادة ما تكون خفيفة وتختفي بعد وقت قصير.</p><p dir="RTL">يجب التوقف عن تناول <strong>سكولتا</strong>&nbsp; وطلب المساعدة الطبية على الفور إذا كان لديك أي من أثار الحساسية التالية:</p><p dir="RTL">&bull; صعوبة في التنفس، مع أو دون تورم في الوجه والشفتين واللسان و / أو الحلق.</p><p dir="RTL">&bull; تورم في الوجه والشفتين واللسان و / أو الحلق، مما قد يسبب صعوبة في البلع.</p><p dir="RTL">&bull; حكة شديدة في الجلد (مع كتل مرتفعة).</p><p dir="RTL">أيضا، يجب التوقف عن تناول <strong>سكولتا</strong>&nbsp; والتحدث إلى الطبيب فورا إذا كان لديك أي آلام غير عادية أو آلام في العضلات والتي قد تستمر لفترة أطول مما كنت تتوقع. أعراض العضلات هي أكثر شيوعا في الأطفال والمراهقين مما هو عليه في البالغين. كما هو الحال مع غيرها من الستاتينات، قد شهد عدد قليل جدا من الناس آثار في&nbsp; العضلات غير سارة ونادرا ما قد تصبح مهددة الحياة والمعروفة باسم انحلال العضلات المخططة.</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الشائعة (هذه قد تؤثر بين 1 من كل 10 و 1 من كل 100 مريض):</strong></p><p dir="RTL">&bull;صداع الرأس</p><p dir="RTL">&bull; آلام في المعدة</p><p dir="RTL">&bull; الإمساك</p><p dir="RTL">&bull; الشعور بالمرض</p><p dir="RTL">&bull; ألم عضلي</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; دوخة</p><p dir="RTL">&bull; زيادة في كمية البروتين في البول - وهذا عادة يعود إلى وضعه الطبيعي من تلقاء نفسه دون الحاجة إلى التوقف عن أخذ أقراص <strong>سكولتا</strong>&nbsp; الخاص بك (فقط <strong>سكولتا</strong> 40 ملغم)</p><p dir="RTL">&bull; داء السكري. هذا هو الأرجح إذا كان لديك مستويات عالية من السكريات والدهون في الدم، يعانون من زيادة في الوزن وارتفاع ضغط الدم. سيقوم طبيبك بمراقبتك أثناء تناولك هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة المحتملة (هذه قد تؤثر بين 1 من كل 100 و 1 من كل 1000 مريض):</strong></p><p dir="RTL">الطفح الجلدي، والحكة أو ردود فعل جلدية الأخرى</p><p dir="RTL">زيادة في كمية البروتين في البول - وهذا عادة يعود إلى وضعه الطبيعي من تلقاء نفسه دون الحاجة إلى التوقف عن تناول أقراص <strong>سكولتا</strong>&nbsp; الخاص بك (فقط <strong>سكولتا</strong>&nbsp; 5 ملغم، 10 ملغم و 20 ملغم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة محتملة (قد تؤثر هذه الأعراض بين 1 من كل 1000 و 1 من كل 10000 مريض):</strong></p><p dir="RTL">&bull; ردود الفعل التحسسية الشديدة - تشمل تورم في الوجه والشفتين واللسان و / أو الحلق وصعوبة في البلع والتنفس وحكة شديدة في الجلد (مع كتل مرتفعة). إذا كنت تعتقد أن لديك رد فعل تحسسي، يجب التوقف عن تناول <strong>سكولتا</strong> وأطلب المساعدة الطبية على الفور</p><p dir="RTL">&bull; تلف العضلات في البالغين - كإجراء وقائي، توقف عن تناول <strong>سكولتا</strong>&nbsp; وتحدث مع طبيبك فورا إذا كان لديك أي ألم أو آلام غير عادية في عضلاتك تستمر لأكثر من المتوقع</p><p dir="RTL">&bull; ألم شديد في المعدة (البنكرياس الملتهب)</p><p dir="RTL">&bull; زيادة في إنزيمات الكبد في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدا محتملة (هذه قد تؤثر على أقل من 1 من كل 10000 مريض):</strong></p><p dir="RTL">&bull; اليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&bull; التهاب الكبد (كبد ملتهب)</p><p dir="RTL">&bull; آثار الدم في البول</p><p dir="RTL">&bull; تلف الأعصاب في ساقيك والذراعين (مثل خدر)</p><p dir="RTL">&bull; الم المفاصل</p><p dir="RTL">&bull;فقدان الذاكرة</p><p dir="RTL">&bull; كبر الثدي في الرجال (التثدي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تشمل الآثار الجانبية ذات التردد غير المعروف:</strong></p><p dir="RTL">&bull; الإسهال (البراز لين)</p><p dir="RTL">&bull; متلازمة ستيفنز جونسون (حالة خطرة في الجلد والفم والعينين والأعضاء التناسلية)</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; ضيق في التنفس</p><p dir="RTL">&bull; وذمة (تورم)</p><p dir="RTL">&bull; اضطرابات النوم، بما في ذلك الأرق والكوابيس</p><p dir="RTL">&bull; صعوبات جنسية</p><p dir="RTL">&bull; اكتئاب</p><p dir="RTL">&bull; مشاكل في التنفس، بما في ذلك السعال المستمر و / أو ضيق في التنفس أو الحمى</p><p dir="RTL">&bull; إصابة في الاوتار</p><p dir="RTL">&bull; ضعف العضلات الذي هو ثابت</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p dir="RTL">-يحفظ الدواء على درجة حرارة لا تتجاوزо30م.</p><p dir="RTL">-لا تستعمل <strong>سكولتا</strong>&nbsp; بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة Exp. يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">-لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي:</strong> روسوفاستاتن.</p><p dir="RTL"><strong>سكولتا&nbsp; 10 ملغم أقراص مغلفة:</strong> كل قرص مغلف يحتوي على روسوفاستاتن كالسيوم ما يعادل 10 ملغم روسوفاستاتن.</p><p dir="RTL"><strong>سكولتا&nbsp; 20 ملغم أقراص مغلفة:</strong> كل قرص مغلف يحتوي على روسوفاستاتن كالسيوم ما يعادل 20 ملغم روسوفاستاتن.</p><p dir="RTL"><strong>سكولتا&nbsp; 40 ملغم أقراص مغلفة:</strong> كل قرص مغلف يحتوي على روسوفاستاتن كالسيوم ما يعادل 40 ملغم روسوفاستاتن.</p><p dir="RTL"><strong>المكونات الأخرى هي:</strong></p><p dir="RTL">&nbsp;فوسفات الكالسيوم اللامائي، بوفيدون متشابك، سيلليلوز دقيق التبلور، لاكتوز، مغنيسيوم إستارات، اوبادراي أبيض OY-L، أكسيد الحديد الأحمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مغلفة</p><p dir="RTL"><strong>الوصف المادي: </strong></p><p dir="RTL"><strong>&bull;سكولتا&nbsp; 10 ملغم أقراص مغلفة:</strong> أقراص دائرية ذات لون وردي محدبة الوجهين موسومة بـ E57 على أحد الجوانب وملساء على الجانب الآخر.</p><p dir="RTL"><strong>&bull;سكولتا&nbsp; 20 ملغم أقراص مغلفة:</strong> أقراص دائرية ذات لون وردي محدبة الوجهين موسومة بـ E55 على أحد الجوانب وملساء على الجانب الآخر.</p><p dir="RTL"><strong>&bull;سكولتا&nbsp; 40 ملغم أقراص مغلفة:</strong> أقراص مغلفة بيضاوية ذات لون وردي غير قابلة للكسر موسومة بـ E54 على أحد الجوانب وملساء على الجانب الآخر.</p><p dir="RTL">إن الأقراص معبأة في أشرطة من الألومنيوم و الألومنيوم ، ثم معبأة في علب كرتونية مع نشرة مطوية.</p><p dir="RTL">حجم العبوة: 30 قرص مغلف (10 أقراص / شريط، 3 أشرطة / العلبة).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL"><strong>صنعت بواسطة: </strong>&nbsp;&nbsp;</p><p dir="RTL">المتحدة للصناعات الدوائية - الأردن لصالح إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تم الموافقة على هذه النشرة بتاريخ أكتوبر2020؛ رقم النسخة : SPM190353
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SCOLTA® 10mg F/C Tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material name                         Function                   Amount(mg)/one tablet
Rosuvastatin calcium         Active material                         10.4**

*equivalent to 10 mg rosuvastatin.
**actual quantity depends on the potency and water content of the API.
For a full list of excipients, see section 6.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
SCOLTA® 10mg F/C Tablets Description: Pink round biconvex tablet embossed with E57 on one 
side, and plain on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolemia </strong></p><p>Adults, adolescents and children aged 6 years or older with primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Homozygous familial hypercholesterolemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p><strong>Prevention of Cardiovascular Events </strong></p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: </strong>Orally</p><p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines. SCOLTA&reg; may be given at any time of day, with or without food</p><p><strong>Treatment of hypercholesterolemia </strong></p><p>The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions. A dose adjustment to the next dose level can be made after 4 weeks, if necessary. In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses, a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolemia at high cardiovascular risk (in particular those with familial hypercholesterolemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed. Specialist supervision is recommended when the 40 mg dose is initiated.</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction, the dose used was 20 mg daily</p><p><strong>Paediatric population</strong></p><p>Paediatric use should only be carried out by specialists. Children and adolescents 6 to 17 years of age (Tanner Stage</p><p>In children and adolescents with heterozygous familial hypercholesterolemia the usual start dose is 5 mg daily. &bull; In children 6 to 9 years of age with heterozygous familial hypercholesterolemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population. &bull; In children 10 to 17 years of age with heterozygous familial hypercholesterolemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population. Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations. Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment. Experience in children with homozygous familial hypercholesterolemia is limited to a small number of children aged between 8 and 17 years. The 40 mg tablet is not suitable for use in paediatric patients</p><p>Homozygous familial hypercholesterolemia In children 6 to 17 years of age with homozygous familial hypercholesterolemia, the recommended maximum dose is 20 mg once daily. A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations. Children and adolescents should be placed on standard cholesterollowering diet before rosuvastatin treatment initiation; this diet should be continued during</p><p>rosuvastatin treatment. There is limited experience with doses other than 20 mg in this population. The 40 mg tablet is not suitable for use in paediatric patients. Children younger than 6 years The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, SCOLTA&reg; is not recommended for use in children younger than 6 years. Use in the elderly A start dose of 5 mg is recommended in patients &gt;70 years. No other dose adjustment is necessary in relation to age. Dosage in patients with renal insufficiency No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance of &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of SCOLTA&reg; in patients with severe renal impairment is contraindicated for all doses. Dosage in patients with hepatic impairment There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9. In these patients an assessment of renal function should be considered. There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease. Race Increased systemic exposure has been seen in Asian subjects. The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients. Genetic polymorphisms Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure. For patients who are known to have such specific types of polymorphisms, a lower daily dose of SCOLTA&reg; is recommended. Dosage in patients with pre-disposing factors to myopathy The recommended start dose is 5 mg in patients with predisposing factors to myopathy. The 40 mg dose is contraindicated in some of these patients.</p><p>Concomitant therapy Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when SCOLTA&reg; is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing SCOLTA&reg; therapy. In situations where co-administration of these medicinal products with SCOLTA&reg; is unavoidable, the benefit and the risk of concurrent treatment and SCOLTA&reg; dosing adjustments should be carefully considered</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SCOLTA® is contraindicated
In patients with hypersensitivity to rosuvastatin or to any of the excipients.
- In patients with active liver disease including unexplained, persistent elevations of serum 
transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal 
(ULN).
- In patients with severe renal impairment (creatinine clearance <30 ml/min).
- In patients with myopathy.
- In patients receiving concomitant ciclosporin.
- During pregnancy and lactation and in women of childbearing potential not using appropriate 
contraceptive measures.
- The 40 mg dose is contraindicated in patients with pre-disposing factors for 
myopathy/rhabdomyolysis. Such factors include:
- Moderate renal impairment (creatinine clearance < 60 ml/min)
- Hypothyroidism
- Personal or family history of hereditary muscular disorders
- Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate
- Alcohol abuse
- Situations where an increase in plasma levels may occur
- Asian patients
- Concomitant use of fibrates.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renal Effects Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of Rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease. The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg. Skeletal Muscle Effects Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in Rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded and caution should be exercised with their combined use. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with Rosuvastatin in post-marketing use is higher at the 40 mg dose. Creatine Kinase Measurement Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started. Before Treatment Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include&nbsp;Renal impairment &bull; Hypothyroidism &bull; Personal or family history of hereditary muscular disorders &bull; Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate &bull; Alcohol abuse &bull; Age &gt;70 years &bull; Situations where an increase in plasma levels may occur &bull; Concomitant use of fibrates. In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started. Whilst on Treatment Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing Rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotizing myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment. No evidence of increased skeletal muscle effects in the small number of patients dosed with Rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of Rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of Rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate. Combination with rosuvastatin and fusidic acid is not recommended. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination. Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or&nbsp;uncontrolled seizures). Liver Effects As with other HMG-CoA reductase inhibitors, Rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease. It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum</p><p>transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose. In patients with secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Rosuvastatin. Protease inhibitors Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Rosuvastatin in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Rosuvastatin doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of SCOLTA&reg; is adjusted. Lactose intolerance Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Interstitial lung disease Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy. Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued. Diabetes Mellitus Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m2 , raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines. Paediatric population The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. No effect on growth, weight, BMI or sexual maturation was detected. Children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in adult</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of co-administered medicinal products on rosuvastatin Transporter protein inhibitors: Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of Rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy. Ciclosporin: During concomitant treatment with Rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers. Rosuvastatin is&nbsp;contraindicated in patients receiving concomitant ciclosporin. Concomitant administration did not affect plasma concentrations of ciclosporin. Protease inhibitors: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure. The concomitant use of Rosuvastatin and some protease inhibitor combinations may be considered after careful consideration of Rosuvastatin dose adjustments based on the expected increase in rosuvastatin exposure. Gemfibrozil and other lipid-lowering products: Concomitant use of Rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin C max and AUC. No pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate. These patients should also start with the 5 mg dose. Ezetimibe: Concomitant use of 10 mg Rosuvastatin and 10 mg ezetimibe resulted in a 1.2 fold increase in AUC of rosuvastatin in hypercholesterolemic subjects. A pharmacodynamic interaction, in terms of adverse effects, between Rosuvastatin and ezetimibe cannot be ruled out. Antacid: The simultaneous dosing of Rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Rosuvastatin. The clinical relevance of this interaction has not been studied. Erythromycin: Concomitant use of Rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin. Cytochrome P450 enzymes: Rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p>Interactions requiring rosuvastatin dose adjustments: When it is necessary to co-administer Rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of Rosuvastatin should be adjusted. Start with a 5 mg once daily dose of rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosuvastatin should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of Rosuvastatin taken without interacting medicinal products, for example a 20 mg dose of Rosuvastatin with gemfibrozil (1.9-fold increase), and a 10 mg dose of Rosuvastatin with combination ritonavir/atazanavir (3.1-fold increase). Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) Interacting drug dose regimen Rosuvastatin dose regimen Change in rosuvastatin AUC* Ciclosporin 75 mg BID to 200 mg BID, 6 10 mg OD, 10 days 7.1-fold</p><p>months Atazanavir 300 mg/ritonavir 100 mg OD, 8 days 10 mg, single dose 3.1-fold &uarr; Simeprevir 150 mg OD, 7 days 10 mg, single dose 2.8-fold &uarr; Lopinavir 400 mg/ritonavir 100 mg BID, 17 days 20 mg OD, 7 days 2.1-fold &uarr; Clopidogrel 300 mg loading, followed by 75 mg at 24 hours 20 mg, single dose 2-fold &uarr; Gemfibrozil 600 mg BID, 7 days 80 mg, single dose 1.9-fold &uarr; Eltrombopag 75 mg OD, 5 days 10 mg, single dose 1.6-fold &uarr; Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg OD, 7 days 1.5-fold &uarr; Tipranavir 500 mg/ritonavir 200 mg BID, 11 days 10 mg, single dose 1.4-fold &uarr; Dronedarone 400 mg BID Not available 1.4-fold &uarr; Itraconazole 200 mg OD, 5 days 10 mg, single dose **1.4-fold &uarr; Ezetimibe 10 mg OD, 14 days 10 mg, OD, 14 days **1.2-fold &uarr; Fosamprenavir 700 mg/ritonavir 100 mg BID, 8 days 10 mg, single dose &harr; Aleglitazar 0.3 mg, 7 days 40 mg, 7 days &harr; Silymarin 140 mg TID, 5 days 10 mg, single dose &harr; Fenofibrate 67 mg TID, 7 days 10 mg, 7 days &harr; Rifampin 450 mg OD, 7 days 20 mg, single dose &harr; Ketoconazole 200 mg BID, 7 days 80 mg, single dose &harr; Fluconazole 200 mg OD, 11 days 80 mg, single dose &harr; Erythromycin 500 mg QID, 7 days 80 mg, single dose 20% &darr; Baicalin 50 mg TID, 14 days 20 mg, single dose 47% &darr; * Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone. Increase is indicated as &ldquo;&uarr;&ldquo;, no change as &ldquo;&harr;&rdquo;, decrease as &ldquo;&darr;&rdquo;. **Several interaction studies have been performed at different SCOLTA&reg; dosages, the table shows the most significant ratio OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily Effect of rosuvastatin on co-administered medicinal products Vitamin K antagonists: As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised&nbsp;Ratio (INR). Discontinuation or down-titration of Rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable. Oral contraceptive/hormone replacement therapy (HRT): Concomitant use of Rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant Rosuvastatin and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women and was well tolerated. Other medicinal products: Digoxin: No clinically relevant interaction with digoxin is expected. Fusidic Acid: As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with rosuvastatin and fusidic acid given concurrently. Therefore, the combination rosuvastatin and fusidic acid is not recommended. If possible, temporary suspension of rosuvastatin treatment is recommended. If unavoidable, patients should be closely monitored. Paediatric population: The extent of interactions in the paediatric population is not known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy SCOLTA&reg; is contraindicated in pregnancy and lactation. Women of child bearing potential should use appropriate contraceptive measures. Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. If a patient becomes pregnant during use of this product, treatment should be discontinued immediately. Breastfeeding Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of SCOLTA&reg; on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, SCOLTA&reg; is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with SCOLTA&reg; are generally mild and transient. Tabulated list of adverse reactions The following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC). The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data). Table 2. Adverse reactions based on data from clinical studies and post-marketing experienc&nbsp;System organ class Common Uncommon Rare Very rare Not known Blood and lymphatic system disorders Thrombocytopenia Immune system disorders Hypersensitivity reactions including angioedema Endocrine disorders Diabetes mellitus1 Psychiatric disorders Depression Nervous system disorders Headache Dizziness Polyneuropat hy Memory loss Peripheral neuropathy Sleep disturbances (including insomnia and nightmares) Respiratory, thoracic and mediastinal disorders Cough Dyspnoea Gastro-intestinal disorders Constipation Nausea Abdominal pain Pancreatitis Diarrhoea Hepatobiliary disorders Increased hepatic transaminases Jaundice Hepatitis Skin and subcutaneous tissue disorders Pruritis Rash Urticaria StevensJohnson syndrome Musculo-skeletal and connective tissue disorders Myalgia Myopathy (including myositis) Rhabdomyolysis Arthralgia Tendon disorders, sometimes complicated by rupture Immunemediated necrotizing myopathy Renal and urinary Haematuri</p><p>&nbsp;</p><p>Renal effects: Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with Rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in 20 mg. A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued. Liver effects: As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. The following adverse events have been reported with some statins: Sexual dysfunction. Exceptional cases of interstitial lung disease, especially with long term therapy. The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose. Paediatric population: Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in children and adolescents compared to adults. In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms: There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Hemodialysis is unlikely to be of benefit</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: HMG-CoA reductase inhibitors ATC code: C10A A07 Mechanism of action Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles. Pharmacodynamic effects Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers Apo B, non HDL-C, VLDL-C, VLDL-TG and increases Apo A-I. Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C and non HDL-C/HDL-C and the Apo B/Apo A-I ratios. A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption: Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%. Distribution: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin. Metabolism: Rosuvastatin undergoes limited metabolism (approximately 10%). Rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less&nbsp;active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity. Excretion: Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 liters/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin. Linearity: Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses. Special populations: Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The pharmacokinetics of rosuvastatin in children and adolescents with heterozygous familial hypercholesterolemia was similar to that of adult volunteers. Race: An approximate 2-fold elevation in median AUC and Cmax in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups. Renal insufficiency: In mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing hemodialysis were approximately 50% greater compared to healthy volunteers. Hepatic insufficiency: In varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with ChildPugh scores above 9</p><p>Genetic polymorphisms: Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of Rosuvastatin is recommended. Paediatric population: Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p> Calcium Phosphate anhydrous,  Crosspovidone,  Microcrystalline Cellulose,  Lactose,  Magnesium Stearate,  Opadry White OY-L,  Red Iron Oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SCOLTA&reg; 10mg F/C Tablets are packed in blisters of Aluminum / Aluminum foil, in carton box with a folded leaflet in pack size of 30 F/C tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma-Saudi 
Almuraba Area
Prince Abdulaziz bin Musaid bin Jalawi Street
Mansour Alrusais Building - F1
Riyadh-KSA
Tel: 00966114010606
Fax: 00966114010606
E-mail: Albaraa.bahhari@mspharma.coM
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February, 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>